The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
Open accessAbstract
OBJECTIVE: Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on to existing glucose-lowering medications in patients with inadequately controlled type 2 diabetes and moderate renal impairment. RESEARCH DESIGN AND METHODS: In this 26-week, double-blind trial, 279 patients with HbA1c 7–10%, BMI 20–45 kg/m2, and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2; MDRD) were randomized (1:1) to once-daily liraglutide 1.8 mg (n = 140) or placebo (n = 139). RESULTS: The estimated treatment difference in HbA1c from baseline to week 26 was −0.66% (−7.25 mmol/mol) (95% CI −0.90 to −0.43 [−9.82 to −4.69]), P < 0.0001). Fasting plasma glucose decreased more with liraglutide (−1.22 mmol/L [−22.0 mg/dL]) than with placebo (−0.57 mmol/L [−10.3 mg/dL], P = 0.036). There was a greater reduction in body weight with liraglutide (−2.41 kg) than with placebo (−1.09 kg, P = 0.0052). No changes in renal function were observed (eGFR relative ratio to baseline: −1% liraglutide, +1% placebo; estimated treatment ratio [ETR] 0.98, P = 0.36). The most common adverse events were gastrointestinal (GI) adverse effects (liraglutide, 35.7%; placebo, 17.5%). No difference in hypoglycemic episodes was observed between treatment groups (event rate/100 patient-years of exposure: liraglutide, 30.47; placebo, 40.08; P = 0.54). The estimated ratio to baseline for lipase was 1.33 for liraglutide and 0.97 for placebo (ETR 1.37, P < 0.0001). CONCLUSIONS: Liraglutide did not affect renal function and demonstrated better glycemic control, with no increase in hypoglycemia risk but with higher withdrawals due to GI adverse events than placebo in patients with type 2 diabetes and moderate renal impairment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike the LEADER and SCALE trials, in the LIRA-RENAL trial liraglutide was found to be ineffective in improving renal outcomes in a sample of 279 diabetic patients with moderate CKD (eGFR 30–59 mL/min/1.73 m2).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
In the citing paper
“The authors found no difference in terms of eGFR and UACR compared with placebo after 26 weeks of treatment [44].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [44]
Citations
Cites
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725 · cited 1×
“Safety assessments included adverse events (AEs), change from baseline to Week 26 in renal function (eGFR [MDRD] (19), urinary albumin:creatinine ratio [UACR]), amylase, lipase and pulse rate.”
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 1×
“Albuminuria is not only a marker for kidney damage but it is also a cardiovascular risk factor (33,34).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Research works printed but not linked: 1
- Scott, 2014, Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial (Abstract), J Am Soc Nephrol, 25, 75A
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationMolecular mechanisms of ROS production and oxidative stress in diabetes
Newsholme, P., Cruzat, V. F., Keane, K. N., Carlessi, R., & de Bittencourt, P. I. H. (2016) · Biochemical Journal · doi:10.1042/bcj20160503c · Cited by 878
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
“13,14 Alternatively, differences between the results in this trial and the encouraging earlier study using recombinant GLP-17 could be due to the cardioprotective roles of GLP-1 metabolites, such as GLP-1(9-36)amide, which act independently of the GLP-1 receptor and are not generated by GLP-1 agonists like liraglutide.”
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Metadata
- Authors
- Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E.
- Affiliations
- University of Leicester (GB)
- Swansea University (GB)
- Weill Cornell Medical College in Qatar (QA)
- Steno Diabetes Center, Gentofte, Denmark
- Clinical Research Development Associates, Rosedale, NY
- Department of Diabetic Nephropathy, Endocrinology Research Centre, Moscow, Russia
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Emory University (US)
- Corresponding author
- Davies, Melanie J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-12-17
- Volume
- 39
- Issue
- 2
- Pages
- 222-230
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2236659707
- Cited by
- 235
- References
- 35
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 17 · 2023: 28 · 2022: 18 · 2021: 19 · 2020: 24 · 2019: 22 · 2018: 28 · 2017: 24 · 2016: 16
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liraglutide, type 2 diabetes, renal dysfunction, glycemic control, HbA1c, fasting blood glucose, weight loss, renal function, lipase, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Gastrointestinal Tract, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. https://app.cochat.ai/papers/10.2337/dc14-2883
- The paper
- Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016). Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. https://doi.org/10.2337/dc14-2883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.